Bio-Rad Laboratories, Randox Laboratories Ltd., and Abbott are dominating the India Diagnostic Controls Market in 2021

India Diagnostic Controls Market is expected to grow with the CAGR of 13.7% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/india-molecular-diagnostic-controls-market

India diagnostic controls market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing diagnostic controls market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In July 2021, Thermo Fisher Scientific Inc. announced that it has collaborated with the Ortho Clinical Diagnosticsin order to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analysers. This collaboration done by the company has increased its sales and demand in the market leading to increased revenue in future. The company's introduction of this new product has boosted its credibility and market demand.

Bio-Rad Laboratories Inc. is dominating player in India diagnostic controls market. The other key players existing in the market includes India diagnostic controls market includes Randox Laboratories Ltd., Abbott, bioMérieux SA, Thermo Fisher Scientific Inc., Asuragen, Inc., Molbio Diagnostics Pvt. Ltd., and SERACARE LIFE SCIENCES among others

India Molecular Diagnostic Controls MarketBio-Rad Laboratories Inc.

Bio-Rad Laboratories Inc. has it base headquarters in California, U.S. and was founded in 1952. The company is focused in development, manufacturing, and marketing, of broad range of innovative product for the life science research and clinical diagnostics market. The company deals in two business segment life science and clinical diagnostic. The company deals in Product portfolio such as life science research, clinical diagnostics, process separators and food science out of which clinical diagnostics is the market focused product portfolio.

  • In June, Bio-Rad Laboratories, Inc. announced that it has undergone partnership with Seegene, Inc. for the development and commercialization of infectious disease molecular diagnostic products. This partnership done by the company has increased its demand and sales in the market.

The company has presence in North America, Latin America, Europe, Asia Pacific. The company has its base subsidiaries in Bio-Rad Korea (Korea), Bio-Rad laboratories S.r.l. (Italy), Bio-Rad S.A ( Canada), Bio-Rad Laboratories GmbH (Germany), Bio-Rad Laboratories (India) among others.

Randox Laboratories Ltd.

Randox Laboratories Ltd. is headquartered in Antrim, U.K.  and was founded in 1982. The company is focused on the development of pioneering tests for a range of common illness such as cancer, cardiovascular disease and Alzheimer’s disease. The company has multiple product categories such as clinical chemistry, analysers, molecular, reagents, quality control, EQA, Veterinary, immunoassay, biosciences and disease markers out of which quality control are the market focused category.  

  • In March, Randox Laboratories Ltd. announced that it has launched new product named ACUSERA D-Dimer Control. This new product launched by the company has increased its sales and demand in the market leading to increased revenue in future.

The company has wide global presence across America, Europe.

Abbott

Abbott is headquartered in Illinois, U.S. and was founded in 1888. The company is focuses on manufacturing products in diagnostics medical devices, nutrition and branded generic pharmaceuticals that help people to live healthier lives. The company provide wide product portfolio such as cardiovascular, diabetic care, diagnostic, neuromodulation, nutritions and medicines among which diagnostics is the market focused category.

  • In September, Abbott launched Panbio COVID-19 Rapid Test in France for supporting the detection of rapidly rising COVID-19 patients in France. This launch of diagnostic test by the company has increased its credibility in the market.

The company has wide global presence across North America, South America, Europe, Asia-Pacific, Middle East and India.

The company has various subsidiaries such Abbott cardiovascular systems, Inc. (U.S), Abbott Nutritional Manufacturing Inc., (U.S.), and Abbott S.r.l (Italy) among others.